Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29181697 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL31399606 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL29101099 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL6759532 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL8898006 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL16114411 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL28648055 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL6062106 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL8898834 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 | |
| SCHEMBL28044906 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4GPR84SPHK1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025010290-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | FFAR1 178/4885FFAR4 429/4885GPR84 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.